Fink Family Office’s Post

Empirical Ventures Year in Review; The vision for Empirical Ventures is to build the premiere DeepTech investor across the UK and Europe. Bringing together a team of PhD scientists with deep domain knowledge as operators, entrepreneurs and investors to build a venture capital fund that is truly differentiated. Last week we brought together LPs, Angel Investors, Portfolio Companies and Stakeholders to celebrate 2024 - kindly hosted at a unique venue by the Fink Family Office and joined by Shadow Secretary of State for Science, Innovation and Technology Alan Mak MP. What a year it has been at Empirical Ventures. With the launch of our first Fund we brought our total AUM to £14m. In 2024 we invested in 9 pre-seed and seed stage DeepTech rounds (Xgenera, Exciting Instruments, MintNeuro, Silveray, Signapse, Neuronostics, Transdermal Diagnostics Ltd, ARGONAUTE RNA LIMITED, MitoRx Therapeutics) tackling everything from semiconductors for neural implants to digital x-ray films to bispecific gene silencing therapies. These companies joined existing portfolio companies (Halo Therapeutics, WASE, OSSTEC, Albotherm, EnsiliTech, CheMastery Group Ltd, Muddy Machines, Zentraxa , QV Bioelectronics) taking the total portfolio to 18. We welcomed two new team members taking the team to 6 people: our two founders Dr Ben Miles, Ph.D. and Johnathan Matlock, supported by Curran Kalha, Ph.D., Claudia Fryer, Trang K. Nguyen and Madeleine Nichols, PhD. We also welcomed three venture partners Alexander Fink, Keith Lipman and Steve Chasan A unique feature of DeepTech is that things take time to develop. Our LPs recognise this requirement to remain patient in the early years of the scientific commercialisation journey. So in this first 2-3 year period we are often looking for signals of positive momentum, 2024 has been tremendously exciting for our portfolio and we believe a number of companies are poised for significant growth in 2025. Finally a big shout out to our investors. Investors that share our vision for backing the best entrepreneurial scientists as they change the very fabric of the world in which we live. A specific shout out to British Business Investments (Mark Barry and Luke W.) and the Regional Angels Co-investment Fund which has been instrumental in increasing the firepower we can deploy into these businesses. In the year that we launched our first fund a special shout out goes to the stakeholders who supported us along the way, a special thanks to the following; SFC Capital Partner (Marguerite Crossfield and Stephen Page) - AIFM RW Blears (Ollie Blears, Lannie Churchill, Bethany Johnson) - Fund Structuring Abel + Imray (Tom Turner) - IP We have big plans for 2025, so please like, follow and support EV as we continue to back scientists who turn theory into action. CAPITAL AT RISK. FOR PROFESSIONAL INVESTORS ONLY.